Lyell Immunopharma Revises Colorectal Cancer Trial After Safety Improvement, Shares Rise
Lyell Immunopharma's stock ticked up in premarket trading after the company amended its LYL273 colorectal cancer trial after a marked reduction in gastrointestinal side effects with prophylaxis. The Phase 1 study has been renamed CARABINER and expanded to include additional cohorts, with plans for up to 60 patients and potential progression into a …